The role of aflibercept in the management of diabetic macular edema

Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Andrew A, Hong, Thomas, Ewe, Shaun Y, Bahrami, Bobak, Broadhead, Geoffrey K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532215/
https://www.ncbi.nlm.nih.gov/pubmed/26273198
http://dx.doi.org/10.2147/DDDT.S62778
_version_ 1782385198829142016
author Chang, Andrew A
Hong, Thomas
Ewe, Shaun Y
Bahrami, Bobak
Broadhead, Geoffrey K
author_facet Chang, Andrew A
Hong, Thomas
Ewe, Shaun Y
Bahrami, Bobak
Broadhead, Geoffrey K
author_sort Chang, Andrew A
collection PubMed
description Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept.
format Online
Article
Text
id pubmed-4532215
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45322152015-08-13 The role of aflibercept in the management of diabetic macular edema Chang, Andrew A Hong, Thomas Ewe, Shaun Y Bahrami, Bobak Broadhead, Geoffrey K Drug Des Devel Ther Review Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept. Dove Medical Press 2015-08-06 /pmc/articles/PMC4532215/ /pubmed/26273198 http://dx.doi.org/10.2147/DDDT.S62778 Text en © 2015 Chang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Chang, Andrew A
Hong, Thomas
Ewe, Shaun Y
Bahrami, Bobak
Broadhead, Geoffrey K
The role of aflibercept in the management of diabetic macular edema
title The role of aflibercept in the management of diabetic macular edema
title_full The role of aflibercept in the management of diabetic macular edema
title_fullStr The role of aflibercept in the management of diabetic macular edema
title_full_unstemmed The role of aflibercept in the management of diabetic macular edema
title_short The role of aflibercept in the management of diabetic macular edema
title_sort role of aflibercept in the management of diabetic macular edema
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532215/
https://www.ncbi.nlm.nih.gov/pubmed/26273198
http://dx.doi.org/10.2147/DDDT.S62778
work_keys_str_mv AT changandrewa theroleofafliberceptinthemanagementofdiabeticmacularedema
AT hongthomas theroleofafliberceptinthemanagementofdiabeticmacularedema
AT eweshauny theroleofafliberceptinthemanagementofdiabeticmacularedema
AT bahramibobak theroleofafliberceptinthemanagementofdiabeticmacularedema
AT broadheadgeoffreyk theroleofafliberceptinthemanagementofdiabeticmacularedema
AT changandrewa roleofafliberceptinthemanagementofdiabeticmacularedema
AT hongthomas roleofafliberceptinthemanagementofdiabeticmacularedema
AT eweshauny roleofafliberceptinthemanagementofdiabeticmacularedema
AT bahramibobak roleofafliberceptinthemanagementofdiabeticmacularedema
AT broadheadgeoffreyk roleofafliberceptinthemanagementofdiabeticmacularedema

Ejemplares similares